Renfeng Guo
Fundador en INFLARX N.V. .
Fortuna: 2 M $ al 30/04/2024
Cargos activos de Renfeng Guo
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| INFLARX N.V. | Director/Miembro de la Junta | 01/12/2007 | - |
| Director Técnico/Científico/I+D | 01/12/2007 | - | |
| Fundador | 01/12/2007 | - |
Historial de carrera de Renfeng Guo
Antiguos cargos conocidos de Renfeng Guo.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| University of Michigan | Corporate Officer/Principal | 01/01/2001 | - |
InflaRx GmbH
 InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Director/Miembro de la Junta | - | - |
| Director Técnico/Científico/I+D | 11/12/2007 | - | |
| Fundador | 25/11/2009 | - |
Formación de Renfeng Guo.
| Norman Bethune Medical University | Doctorate Degree |
Estadísticas
Internacional
| Alemania | 3 |
| China | 2 |
| Estados Unidos | 2 |
Operativa
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| INFLARX N.V. | Health Technology |
| Empresas privadas | 1 |
|---|---|
InflaRx GmbH
InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Health Technology |
- Bolsa de valores
- Insiders
- Renfeng Guo
- Experiencia
